Circulating cartilage oligomeric matrix protein in juvenile idiopathic arthritis

被引:10
作者
Lewander, P. [1 ,2 ]
Dahle, C. [1 ,3 ]
Larsson, B. [4 ]
Wettero, J. [1 ]
Skogh, T. [1 ,5 ]
机构
[1] Linkoping Univ, Div Neuro & Inflammat Sci, Dept Clin & Expt Med, Fac Med & Hlth Sci, SE-58183 Linkoping, Sweden
[2] Cty Council Ostergotland, Dept Paediat, Linkoping, Sweden
[3] Cty Council Ostergotland, Dept Clin Immunol & Transfus Med, Linkoping, Sweden
[4] Cty Council Ostergotland, Clin Chem Lab, Linkoping, Sweden
[5] Cty Council Ostergotland, Heart & Med Ctr, Rheumatol Clin, Linkoping, Sweden
关键词
RHEUMATOID-ARTHRITIS; GROWTH-FACTOR; JOINT DAMAGE; SERUM; COMP;
D O I
10.1080/03009742.2016.1192681
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Raised serum cartilage oligomeric matrix protein (sCOMP) has been reported to predict erosive disease in early rheumatoid arthritis (RA). In juvenile idiopathic arthritis (JIA), subnormal sCOMP levels have been associated with ongoing inflammation and growth retardation. In this study we aimed to assess sCOMP, C-reactive protein (CRP), and insulin-like growth factor (IGF)-1 in children/adolescents with JIA and in referents.Method: We enrolled 52 JIA patients at planned outpatient visits and 54 inpatients with ongoing infection (infection referents'). A total of 120 referents testing negative for immunoglobulin (Ig)E-mediated allergy (IgE referents') served as controls. All serum samples were analysed for COMP, IGF-1, and CRP.Results: The average sCOMP level was highest among the IgE referents and lowest among the infection referents. In the JIA patients, the level of sCOMP was not associated with the level of CRP or with clinical signs of disease activity.Conclusions: The results of this study do not support routine clinical analysis of sCOMP levels in patients with JIA.
引用
收藏
页码:194 / 197
页数:4
相关论文
共 17 条
[11]   Prognostic laboratory markers of joint damage in rheumatoid arthritis [J].
Lindqvist, E ;
Eberhardt, K ;
Bendtzen, K ;
Heinegård, D ;
Saxne, T .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (02) :196-201
[12]   COMP (cartilage oligomeric matrix protein) is synthesized in ligament, tendon, meniscus, and articular cartilage [J].
Müller, G ;
Michel, A ;
Altenburg, E .
CONNECTIVE TISSUE RESEARCH, 1998, 39 (04) :233-244
[13]   Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab [J].
Nakajima, Shoko ;
Naruto, Takuya ;
Miyamae, Takako ;
Imagawa, Tomoyuki ;
Mori, Masaaki ;
Nishimaki, Shigeru ;
Yokota, Shumpei .
MODERN RHEUMATOLOGY, 2009, 19 (01) :42-46
[14]   Solid-phase classical complement activation by C-reactive protein (CRP) is inhibited by fluid-phase CRP-C1q interaction [J].
Sjowall, Christopher ;
Wettero, Jonas ;
Bengtsson, Torbjorn ;
Askendal, Agneta ;
Almroth, Gunnel ;
Skogh, Thomas ;
Tengvall, Pentti .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 352 (01) :251-258
[15]   Up-regulation of cartilage oligomeric matrix protein gene expression by insulin-like growth factor-I revealed by real time reverse transcription-polymerase chain reaction [J].
Tian, Hua ;
Stogiannidis, Ioannis .
ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2006, 38 (10) :677-682
[16]   Increased cartilage turnover and circulating autoantibodies in different subsets before the clinical onset of rheumatoid arthritis [J].
Turesson, Carl ;
Bergstrom, Ulf ;
Jacobsson, Lennart T. H. ;
Truedsson, Lennart ;
Berglund, Goran ;
Saxne, Tore .
ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (03) :520-522
[17]  
Urakami T, 2006, J RHEUMATOL, V33, P996